

中国医学科学院图书馆 药学资源介绍

葛红梅

ge.hongmei@imicams.ac.cn



图书馆药学相关资源



R & D Insight 1994 to March 30, 2009




Thieme Pharmaceutical Substances



R & D Insight

- ◆ 学科属性：药学、化学
- ◆ 简介：R&D Insight 作为当今最药物研发的最重要数据库之一，追踪，研究药物生命周期的各项信息。
- ◆ 可使用的范围：医科院京内各所院（1994年—）



Pharmaceutical Substances

- ◆ 学科属性： 药学
- ◆ 简介： **Pharmaceutical Substances** 数据库是关注于药物合成、专利文献和应用实践的专业数据库，提供市场时事信息。
- ◆ 可使用的范围： 医科院各所院



Pharmaprojects

- ✿学科属性：药学
- ✿简介：世界药物研制开发处于领先地位的智能型数据库。它监控着国际上处于开发阶段的每一个重要新药，跟踪着国际上处于研发活跃阶段的候选药物，提供给客户产品开发的全面资料。
- ✿可使用的范围：校园网





✿学科属性：药学

✿试用时间：2009.4.1-15

✿帐号：zqin

密码：j2980a

✿网址：

http://integrity.prous.com/material/Integrity_Login+Searching

✿可使用的范围：校园网及药学相关院所



http://www.library.imicams.ac.cn/



中国医学科学院 中国协和医科大学
医学信息研究所 图书馆
Institute of Medical Information / Medical Library, CAMS & PUMC

首页 | 服务指南 | 信息资源 | 信息服务 | 信息研究 | 教育培训

+ English

国家科技图书文献中心
医学图书馆

站内搜索 搜 XML



| 服务指南

- 读者向导
- 借阅查询
- 关于我们
- 所馆长信箱
- 所馆内网



| 馆藏文献

- 馆藏目录
- 全国生物医学期刊联目
- NSTL联合目录
- CSDL期刊联合目录
- 新书通报



| 数字资源

- 全文期刊
- 网络数据库
- 多媒体数据库
- 电子图书
- 特色资源
- NSTL开通电子期刊



| 信息服务


- 全文传递
- 查新查引
- 参考咨询
- 出版物

| 信息研究

- 知识管理

| 卫生政策与管理研究中心

- 卫生改革发展战略研究
- 重大疾病防治战略研究
- 医学科技发展战略研究
- 农村卫生、社区卫生与妇幼保健
- 循证医学与医院管理
- 卫生技术评估
- 政策法规与相关文献
- 工作动态



网络数据库:字顺排序

特色资源

WSTL开通电子期刊

网络数据库

如果您不在开通的IP范围内，并且您是经过授权的用户，可以通过登录代理服务器的方式访问。 [使用说明](#)

数据库名称	学科分类	访问控制	详细
AMED 《辅助医学与替代医学数据库》 (1985-)	辅助医学	IP控制	详细
Biosis Preview 《生物学文摘》 (1990-)	医学综合	IP控制	详细
Blackwell Synergy	医学综合	IP控制	详细
BMJ Clinical Evidence	医学综合	IP控制	详细
BMJ Journals Collection	医学综合	IP控制	详细
CINAHL 《护理和保健数据库》 (1982-)	护理学	IP控制	详细
Clinical e-guide	临床	IP控制	详细
Cochrane 《循证医学数据库》	循证医学	IP控制	详细
CSHProtocols	医学、生物学、农业、化学	IP控制	详细
Derwent Innovation Index	专利	本馆内	详细
Dictionary of Information Science and Technology Database	信息科学	IP控制	详细
Embase 《荷兰医学文摘》 (网络版)	医学综合	IP控制	详细
Elsevier Sciencedirect	医学综合	IP控制	详细



Pharmaprojects



Pharmaprojects

- ★ **Pharmaprojects**（药物综合信息数据库）
该数据库是英国著名的Informa Healthcare出版的一个反映世界范围内新药研究、开发生态的信息资料，是从事医药生产、科研、教学、经营管理的人员和医疗卫生工作者及时了解世界范围内药物研究开发进展和动态的必备工具。



Pharmaprojects数据来源

- ★ 公开渠道包括期刊、学术资料和会议论文等文献 e.g. journals, MIMS, PubMed, conferences and abstracts, analysts reports
- ★ 非公开渠道来自与药物公司相关人员的访谈，国际会议和各种调研活动
- ★ 其它 e.g. Scrip, Target



Pharmaprojects

- ✦ 截止到今天，共报道**1,667**家药品制造商研制开发的、覆盖**218**个治疗领域的**36,778**余种药品，并及时对新药研究、开发信息进行跟踪。
- ✦ 提供全文格式，每周更新数据，数据追溯到**1980**年。

Pharmaprojects 内容

★ 研究开发中的药物信息

每个药物都包含**主要信息**:药物名称、开发阶段、各国上市情况;**该药物开发公司的情况**:原始开发公司、国家、开发状况、上市国家;**药理数据**:药效分类及代号、药物用于该适应证的开发状况、药理作用描述、适应症描述、给药途径等;**化学数据**:化合物代号、**CA**注册号、分子量、分子式、化学名、结构式;**专利情况**:专利国家、专利号码、专利优先号、优先日期等;**各国上市情况**:上市国家、上市情况、上市时间、批准情况等;**主要事件**:记录了该药物开发过程中的重大事件;



Pharmaprojects内容

- ✦ 开发厂商及科研项目信息

开发厂商内容包括公司概况以及该公司研究开发的药物、公司业务活动、主要子公司及其附属机构、与其他子公司、学术机构的重要合同、协议、最近的财经状况、与产品许可转让负责人联系的途径、厂商的地址、电话、传真等。

全面了解某公司新药研究开发的总体情况以及各个品种的进展状况。



Pharmaprojects 内容

- ✱ 治疗领域药品信息

根据药物的治疗作用代码对药物进行了专门的细分。

- ✱ 广泛上市或中止开发的药品及许可转让信息

收录了被中止研究开发、撤销或长久未见研究开发报道的药物或化合物的信息。并介绍了中止开发的药物曾经达到的阶段,还有新药许可转让机会。



Pharmaprojects 内容

- ★ 化学结构及化合物的药理活性信息

化学结构信息有化合物结构图,分子式、分子量、美国化学文摘化学物质登记号及创制者。

数据库网址:

http://www.pharmaprojects.com/

Home Subscribers Services About Us

Pharma projects **CLICK HERE FOR A LIVE WEBEX DEMONSTRATION**

Conference Reports Drug Targets Companies Update Links

Pharmaceutical R&D Pipeline News

Company Analysis - Mergers & Acquisitions

The pharmaceutical industry in the coming year

The pharmaceutical industry has always been characterised by mergers and acquisitions (M&A), with deals often running into tens of billions of dollars. This was thought to have reached a peak in 2000, with mergers establishing such 'mega-companies' as GlaxoSmithKline (GSK). However, the M&A market did not slow down even in the aftermath of these megadeals, with further record years in 2006-2007.

In 2007 there was a total volume of US\$79.5 billion in M&A deals. Experts query whether this trend can continue indefinitely. The costs, upheavals and sometimes less-than successful outcomes have had repercussions, and the continued readiness of big companies to swallow each other whole is in doubt. Almost inevitably, 2008 saw a massive decrease in the volume of M&A deals, with the first three quarters of 2008 only reaching a value of US\$28.9 billion. Does this mean that the appetite for M&A has finally been sated?

[read full article >>](#)

Latest R&D News

Mergers, Acquisitions & Joint Ventures

Our news is available via RSS

Company Analysis

Drug development strategies of the key players in Pharmaceutical R&D..

Therapy Analysis

A therapeutic insight into R&D trends in the pharmaceutical industry..

What can you do with Pharmaprojects' R&D pipeline

Newsletter Signup

Email:

Company:

Pharma R&D Pipeline Intelligence

Our pharmaceutical research commentary & drug development news are derived from Pharmaprojects' R&D pipeline intelligence data. Pharmaprojects' research & development pipeline intelligence is your answer to an increasingly competitive pharmaceutical market... [..more about us](#)

© library of CAMS & PUMC

projects

Pharmaprojects

✱ 使用说明：请访问

<http://www.pharmaprojects.com/subscribers/install.htm>将检索软件下载到计算机，并进行安装。安装完毕后需进行注册，注册后用个人信箱登录，使用时访问安装的软件即可。

✱ 软件版本：**Pharmaprojects Version 5.2**



<http://www.pharmaprojects.com/subscribers/install.htm>

The screenshot shows the website's navigation bar with links for Home, Subscribers, Services, and About Us. A search bar is present with options for Search Support, Install/Maintain, and Admin Login. The main content area features a large image of a globe with the Pharmaprojects logo. Below this are two boxes for 'Company Analysis' and 'Therapy Analysis'. The central focus is the 'Install & Maintain' section, which includes instructions and a list of steps for installation and maintenance. To the right, there are sections for 'Search Training' and 'Search tip of the month'.

Home Subscribers Services About Us

CURRENT MEDICAL RESEARCH and Opinion® Request your trial now.

Search Support Install/Maintain Admin Login

Pharma projects

Company Analysis

Drug development strategies of the key players in Pharmaceutical R&D..

Therapy Analysis

A therapeutic insight into R&D trends in the pharmaceutical industry..

Install & Maintain

Follow the steps below to install or update the Pharmaprojects Search Tool
If you encounter any issues make a note of what you are trying to accomplish and follow the troubleshooting process detailed below.

Install

1. Verify system requirements
2. Download and run installer
3. Log in to add the licensed users to your account

Maintain

1. read about the Version 5.2 features
2. Download and run update

Troubleshoot

1. FAQ
2. Contact tech support

Search Training




Unlock the power of the search functionality... request training now

Search tip of the month




Try our time saving tip of the month

登录



Pharmaprojects Web Login

 Please enter your email address to login

Email Address:

Remember my login details

Login Cancel

Login Help



检索界面

- * Main Details
- * Company/Status Data
- * Activity Data
- * Target Data
- * Pharmacokinetics
- * Chemical Data
- * Patent Data
- * Country Data
- * Ratings
- * Major Events
- * Alert Service
- * Latest change

Pharmaprojects V5.2 (Web)

Quick Search

type here GO

search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

View

Web

New Open Save

Drug Profile Search - W/C 22 [338]

- Main Details
- Company/Status Data
- Activity Data
- Target Data
- Pharmacokinetics
- Chemical Data
- Patent Data
- Country Data
- Ratings
- Major Events
- Alert Service
- Latest Change

Hits	And/Or	(...)	Group	Expression	Value	(...)
------	--------	-------	-------	------------	-------	-------

Copy Export Help

Add

Delete

Clear

Replace

(...)

(.X.)

Search

Results

Profile

Graph

Quick Search

type here

Drug Profile Search - W/C 22 Mar 2009
[338]

Find: |

- search**
- Drug Profile Search
 - Structure Search
 - Trend Analysis
 - Company Profile Search
 - Therapy Profile Search
 - Search History

- [-] Main Details
 - Drug Name
 - Drug Name Includes
 - Active, Ceased, Fully Launched
 - Accession Number
 - Detailed Information
- [-] Company/Status Data
 - World Status
 - Company
 - Company R&D Pipeline
 - Company Research Focus
 - Originator
 - Originator Country
 - Originator Status
 - Licensee
 - Licensee Country
 - Licensee Status
 - Licensed-Out Drug
- [+] Activity Data
- [+] Target Data
- [+] Pharmacokinetics

- Drug Name
- (+)-12-oxocalanolide
- (+)-calanolide A
- (+)-calanolide B
- (+)-DDMS
- (+)-didesmethyisibutramine
- (+)-discodermolide
- (+)-DMZ
- (+)-FDI-CBI
- (+)-fluprostenol
- (+)-L-viniferin
- (+)-mefloquine, Vernalis
- (+)-norcisapride
- (+)-phenserine
- (+)-RP 59037
- (+)-zileuton, Cornerstone
- (+)-zopiclone
- (-)-3PPP, Maryland

Hits	And/Or	(...)	Group	Expression	Value	(...)
------	--------	-------	-------	------------	-------	-------

Standard Search

Pharmaprojects V5.2 (Web)

Quick Search

type here

search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

View

Web

Drug Profile Search - W/C [338]

New Open Save

- Main Details
 - Drug Name
 - Drug Name Includes
 - Active, Ceased, Fully Lau
 - Accession Number
 - Detailed Information
- Company/Status Data
 - World Status
 - Company
 - Company R&D Pipeline
 - Company Research Focu
 - Originator
 - Originator Country
 - Originator Status
 - Licensee
 - Licensee Country
 - Licensee Status
 - Licensed-Out Drug
- Activity Data
- Target Data
- Pharmacokinetics

Pharmaprojects V5 Help

隐藏 后退 打印 选项(O)

目录(C) 索引(I)

- Recent enhancements
- Welcome to Pharmaprojects Version 5.2
- The Pharmaprojects Data Explained
 - The Pharmaprojects data explained
 - Drug Profiles
 - Drug Profiles Introduction
 - Accession number
 - Drug Name**
 - World Status
 - Pharma Status
 - Latest change
 - Originator
 - Originator Development status
 - Originator Country
 - Licensee Country
 - Licensee
 - Licensee Development Status
 - Therapy Description or Code
 - Pharmacology Description or C

Drug Name

The drug's unique Generic or International Non-proprietary Name (INN) will be used primarily, where one has been granted.

For many early-stage compounds, the only identity available may be a company research code. In these cases this will be the primary drug name assigned to the product profile.

Synonyms - alternative names, codes or brand names of launched products are listed below the generic name.

- (+)-menloquine, verrians
- (+)-norcisapride
- (+)-phenserine
- (+)-RP 59037
- (+)-zileuton, Cornerstone
- (+)-zopiclone
- (-)-3PPP, Maryland

Hits	And/Or	(...)	Group	Expression	Value	(...)

Results

Profile

Graph

检索结果

- ✱ Drug profiles
- ✱ Therapy profiles
- ✱ Company profiles

DRUG PROFILE

Accession No: 26051

Main Details

Drug Name	World Status	Pharma Status
denosumab	Phase III Clinical Trial	Active

AMG-162
AMGN-0007
anti-OPGL MAb, Amgen

Latest Change

Updated On	By	Latest Change
26 Jul 2006	AG	Results of Phase II nscic and breast cancer trials and update on Phase III trials reported

Company Status Data

Originator	Country	Development Stage
Amgen	USA	Phase III Clinical Trial

Activity Data

Therapy Description	Code	Therapy Status
Monoclonal antibody, human	T3A2	Phase III Clinical Trial
Osteoporosis treatment	M5A	Phase III Clinical Trial
Anticancer, immunological	K3	Phase III Clinical Trial
Antiarthritic, immunological	M2C	Phase II Clinical Trial

© library of **Pharmacology Description**
Osteoclast inhibitor

Code
OSTEOCL-



COMPANY PROFILES

Abbott

Abbott Laboratories
100 Abbott Park Road
Abbott Park
IL 60064-3500
USA

Established 1888
Ownership Public
Research Focus Pharmaceutical
Total Sales (\$US) 22,337.8 (Dec 05)
Pharma Sales (\$US) 13,600.0 (Dec 05)
Scrip Ranking 12

Phone Number +1 847 937 6100

Web Address www.abbott.com

Licensing contact

Global Licensing & Business Development
Dept R50A, Building AP34
200 Abbott Park Road
Abbott Park,
IL 60064-6187
Phone: +1 847 935 8991
Fax: +1 847 937 1771
E-mail: licensing@abbott.com

Richard W Ashley, Executive V-P, Corporate Development

Updated by EW on 16/5/2006.

The company

Abbott Laboratories is a manufacturer and marketer of pharmaceutical, nutritional, hospital and laboratory products. It is a leader in the fields of pharmaceuticals and hospital and laboratory products. Abbott's specialist areas are immune, neurologic, urologic, metabolic & infectious diseases and cancer.



Therapy Profiles

ANTIVIRAL, ANTI-HIV (J5A)

see also: Immunostimulant, anti-AIDS ([I1A](#)); Antiviral, interferon ([J5B](#)); Antiviral ([J5Z](#)); Prophylactic vaccine ([J7A1](#)); Therapeutic vaccine ([J7A2](#)); Recombinant vaccine ([T2B](#)).

MARKET RATING: 2 (worldwide sales of US\$501-2000 million per year)

THERAPEUTIC DEFINITIONS

The human immunodeficiency virus, or HIV, is a virus which attacks the immune system, generally leading to Acquired Immunodeficiency Syndrome (AIDS). HIV is a lentivirus, with a genome of RNA and a glycoprotein envelope. The envelope glycoprotein gp120 can bind to receptors on human CD4 (T4) lymphocytes, cells which are normally involved in defence against invading organisms. Once inside the cell, the virus uses its own enzyme, reverse transcriptase, to make a DNA copy of its genome, which can then insert into the host cell's genome. From here, a combination of host and viral enzymes are used to make new virus particles which burst from the cell, killing it. Syncytial formation can also occur.

Infection with HIV follows an unusual course. After the initial infection, an acute phase is seen which lasts for only a few weeks. This is followed by seroconversion and an asymptomatic phase. This stage commonly lasts for around ten years, during which the patient may have no clinical signs of infection, and infection can only be detected by the presence of antibodies to HIV or measurement of viral load in the bloodstream. However, viral replication continues at a high level during this 'latent' phase, and the virus and the immune system are involved in a titanic struggle, which eventually wears the body's defences out. The blood viral load is used as a measure of expected rate of progression of the disease. When it rises, and CD4 cell depletion subsequently accelerates, clinical manifestations begin or worsen. This usually occurs when CD4 cell levels fall below 200 cells/mm³. Opportunistic infections and certain cancers may develop in such individuals. These are usually the ultimate cause of death in AIDS patients. However, HIV itself has some other direct clinical effects, particularly on the gastrointestinal and neurological systems. Raised TNF levels in AIDS patients can also cause cachexia (wasting). It is thought the course of the disease may be affected by host factors and a number of other cofactors.

实例一

Pharmaprojects V5.2 (Web)

Quick Search

type here

search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

View

Web

New Open Save Save As Delete Print Copy Export Help

Drug Profile Search - W/C 22 Mar 2009 [338]

Find:

- Main Details
- Company/Status Data
 - World Status
 - Company
 - Company R&D Pipeline
 - Company Research Focus
 - Originator
 - Originator Country
 - Originator Status
 - Licensee
 - Licensee Country
 - Licensee Status
 - Licensed-Out Drug
- Activity Data
- Target Data
- Pharmacokinetics
- Chemical Data
- Patent Data
- Country Data
- Ratings
- Major Events

Company

- Abbott
- Abbott Bioresearch Center {Abbott}
- ABC {Inactive}
- Abeille Pharmaceuticals
- Abello {Merck & Co}
- Abeome
- AbGenomics
- ABI {IBI}
- Abic {Teva}
- Abiogen
- Able Laboratories {Inactive}
- Ablynx
- Abraxis BioScience
- AC Immune
- Acacia Pharma
- ACADIA

Hits	And/Or	(...)	Group	Expression	Value	(...)
598			Company	=	Abbott	
=598						

Add Delete Clear Replace (...) (.X.) Search Results Profile Graph

实例一

Pharmaprojects V5.2 (Web)

Quick Search

GO

Report: New Report Search: Untitled Search 4 Hits: 598

Originator	Generic Name	World Status	Any Therapy Code	Any Therapy Description
Abbott	11 β -HSD1 inhibs, Abbott	No Development Reported	A17 C10 C2B9	Metabolic and enzyme disorders Hypolipaeamic/Antiatherosclerosis Antihypertensive, other
Abbott	5'd-5IT	No Development Reported	N2Z	Analgesic, other
Abbott	5-HT5A antagonists, Abbott	No Development Reported	N5A1 N10A N8A N2Z N11Z	Neuroleptic Antidepressant Antimigraine Analgesic, other Neurological
Abbott	7/31-PtCl2	No Development Reported	K1B	Anticancer, alkylating
Abbott	A-104954	No Development Reported	J3Z	Antibacterial, other
Abbott	A-108835	No Development Reported	J5Z	Antiviral, other
Abbott	A-121798	No Development Reported	M2Z R8A A18Z	Antiarthritic, other Antiasthma Alimentary/Metabolic,

search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

View

Web

Add

Delete

Hide

Show All


Results

Profile


Graph

Back

实例一



实例一



实例一

Pharmaprojects V5.2 (Web)

Quick Search

type here

search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

View

Web

New Open Save Save As Delete Print Copy Export Help

Drug Profile Search - W/C 22 Mar 2009 [338]

Find:

- Pharmacology By Therapy
- Therapy By Pharmacology
- Indication Grouping
 - Alimentary/Metabolic Products
 - Anti-infective Products
 - Anticancer Products
 - Antiparasitic Products
 - Blood and Clotting Products
 - Cardiovascular Products
 - Dermatological Products
 - Genitourinary (including sex hormones)
 - Hormonal Products (excluding sex hormones)
 - Immunological Products
 - Miscellaneous Products
 - Musculoskeletal Products
 - NA/Unspecified
 - Neurological Products
 - Respiratory Products
 - Sensory Products
- Primary Indication

Anti-infective Products

- Infection, HIV/AIDS
- Infection, HTLV prophylaxis
- Infection, human metapneumovirus prophylaxis
- Infection, human papilloma virus
- Infection, human papilloma virus prophylaxis
- Infection, influenza virus
- Infection, influenza virus prophylaxis
- Infection, Japanese encephalitis virus prophylaxis
- Infection, Junin virus
- Infection, Kawasaki disease
- Infection, Lassa virus
- Infection, Lassa virus prophylaxis
- Infection, leprosy
- Infection, Lyme disease
- Infection, Lyme disease prophylaxis
- Infection, Marburg virus

Hits	And/Or	(...)	Group	Expression	Value	(...)
598			Company	=	Abbott	
919	AND		Anti-infective Products	=	Infection, HIV/AIDS	
=12						

Add

Delete

Clear

Replace

(...)

(.X.)

Search


Results

Profile

Graph

实例二

Search Results



Copyright © Informa UK Ltd 2009

Links to PubMed

The screenshot displays the Pharmaprojects V5.2 (Web) interface. The main content area shows search results for tacrolimus, including sections for Phase II, Phase I, and Preclinical studies. A yellow arrow points to the 'Search' button in the left sidebar. The interface includes a 'Quick Search' bar at the top, a sidebar with various search options, and a right-hand navigation panel.

Quick Search
type here

Search

Standard Search

1/1

Formulation is in Phase III trials in Japan for vernal conjunctivitis. An oral capsule formulation is in Phase III trials in Japan and the US for organ transplant rejection (Company pipeline, Fujisawa, 25 Feb 2004; 1st Qtr Rep, Fujisawa, 2005). It is in Phase III trials for psoriasis (Scrip Daily Online, 4 Apr 2006, [S00916434](#)). Phase III trials in the US and Phase II in Europe (Company pipeline, Astellas, May 2006).

Phase II
In a randomized, double-blind Phase II trial in 213 patients with moderate-to-severe atopic dermatitis, the median decreases in the summary score for dermatitis on the trunk and extremities after 3wk of treatment with 0.03, 0.1 and 0.3% tacrolimus ointment were 66.7, 83.3 and 75%, respectively of 22.5% for placebo (NEJM, 1997, 337, 816, [PMID:9295241](#)). In a 3mth renal transplantation study, it demonstrated possible synergy with rapamycin (qv) (Press release, Fujisawa, 10 Dec 2001). It is in a European and US Phase II safety and efficacy study in 160 patients with dry eye syndrome, conducted by Sucampo (Press release, Sucampo, 15 Jul 2003). An inhalable formulation is in Phase II trials for asthma in Europe and the US (Scrip Daily Online, 31 Oct 2002, [S00776932](#) & 11 Jul 2005, [S00888420](#)). A US Phase II trial of a gel formulation for psoriasis has been terminated (Scrip Daily Online, 11 Jul 2005, [S00888420](#)).

Phase I
A trial in 30 patients with moderate-to-severe hand dermatitis is planned. Patients will receive a tapering dose of prednisone po x3wk and randomly assigned to apply tacrolimus 0.1% or its vehicle bid x12wk. The primary endpoint is reduction in eczema recurrence (63rd Meet Am Acad Dermatol (New Orleans), 2005, Abs P801). It was in early clinical development for stroke (Direct communication, Fujisawa, 22 Jun 2001). In healthy volunteers, 5mg po had a bioavailability, t1/2, Tmax, Cmax, AUC, Vd and Cl of 18%, 34.8hr, 1.6hr, 29.7ng/ml, 243ng/hr/ml, 1.94l/kg and 0.041l/hr/kg, respectively (Product insert, tacrolimus, 2002).

Preclinical
In rats with collagen-induced arthritis, tacrolimus 1.8mg/kg suppressed paw swelling, histological changes in the knee joint and radiographic changes in the hind paw. It also recovered the decrease in bone mineral density in the femora. At 3.2mg/kg, it markedly reduced TNF- α expression (Inflamm Res, 2003, 52, 524, [PMID:14991082](#)). In NC/Nga mice, a 0.1-1% ointment formulation suppressed development of dermatitis and was effective against established dermatitis by suppressing CD4 cells, mast cells, eosinophils, IL-4, IL-5 and IgE (Jpn J Pharm, 1998, 76, 175). Updated by IL on 25/4/2006.

Additional Clinical Information
Post-Marketing
In 9 patients with moderate-to-severe steroid-refractory ulcerative colitis given tacrolimus 0.15mg/kg po daily, all patients responded within 1-2wk. After 12wk, 6 patients (67%) were in complete remission, 2 (22%) had mild-to-moderate disease activity and 1 patient (11%) underwent colectomy. At 21mth follow-up, 6/9 patients (67%) had their colon in situ, 2 patients developed severe side-effects, and mild

Pharmaprojects V5.2 (Web)

Quick Search

Find Next Print Copy Export Help

type here GO

Search

- Drug Profile Search
- Structure Search
- Trend Analysis
- Company Profile Search
- Therapy Profile Search
- Search History

Standard Search

- View
- Web

1/1

Next Previous Print All Export All Results Profile Graph Back

Formulation is in Phase III trials in Japan for vernal conjunctivitis. An oral capsule formulation is in Phase III trials in Japan and the US for organ transplant rejection (Company pipeline, Fujisawa, 25 Feb 2004; 1st Qtr Rep, Fujisawa, 2005). It is in Phase III trials for psoriasis (Scrip Daily Online, 4 Apr 2006, [S00916434](#)). Phase III trials in the US and Phase II in Europe for RA were discontinued (Company pipeline, Astellas, May 2006).

Phase II:

In a randomized, double-blind Phase II trial in 213 patients with moderate-to-severe atopic dermatitis, the median decreases in the summary score for dermatitis on the trunk and extremities after 3wk of treatment with 0.03, 0.1 and 0.3% tacrolimus ointment were 66.7, 83.3 and 75%, respectively of 22.5% for placebo (NEJM, 1997, 337, 816, [PMID:9295241](#)). In a 3mth renal transplantation study, it demonstrated possible synergy with rapamycin (qv) (Press release, Fujisawa, 10 Dec 2001). It is in a European and US Phase II safety and efficacy study in 160 patients with dry eye syndrome, conducted by Sucampo (Press release, Sucampo, 15 Jul 2003). An inhalable formulation is in Phase II trials for asthma in Europe and the US (Scrip

NCBI PubMed A service of the National Library of Medicine and the National Institutes of Health My NCBI Sign In Register

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

All: 281 Review: 33

Items 1 - 20 of 281 Page 1 of 15 Next

1: [Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S.](#) Related Articles, Links

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997 Sep 18;337(12):816-21. PMID: 9295241 [PubMed - indexed for MEDLINE]

2: [Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM.](#) Related Articles, Links

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group.



能帮助您：

- ✿ 跟踪国际上的新药开发生态
- ✿ 监视竞争对手行为
- ✿ 寻找新药报批机会
- ✿ 搜寻药物靶蛋白
- ✿ 进行市场收益分析
- ✿ 市场合作开发伙伴

WWW.PHARMAPROJECTS.COM

获得更多信息！



<http://www.pjbpubs.com/pharmaprojects/index.htm>



Pharmaprojects

Login

For your FREE online Pharmaprojects demonstration - [click here!](#)

Pharmaprojects

Make Pharmaprojects your homepage

Pharmaprojects - Tracking global pharma R&D since 1980

Manage all your research needs with Pharmaprojects

With over 7,000 drug candidates under active development at any time, you need an effective way of analyzing, monitoring, tracking and benchmarking pharmaceutical R&D to maintain your competitive advantage. The Pharmaprojects database provides the tools for you to do so whilst saving you research time and money.

Each of the 36,500+ drugs tracked in our database has their own profile, detailing the compound's history and progress to date, so it's all the information you need in one place. As with our company and therapy profiles. See examples [here](#).

Consider us the experts! We have over 25 years of research experience, and a strict editorial policy - ensuring you're kept fully up-to-date with information that you can rely on.

[Take a look at our FREE product demonstration >>](#) [Register for our FREE monthly newsletter >>](#)

Who can Pharmaprojects benefit? Press Releases:

Internet | Protected Mode: On 100%



✿ 数据库不能正常访问或推荐数据库，请联系
期刊部 周琴

电话：010-65122901

E-Mail: zhouqin@imicams.ac.cn

✿ 文献检索与传递服务相关问题，请联系
文献服务与流通部 李越

电话：010-65143177

E-Mail: liyue@imicams.ac.cn



欢迎大家使用各种资源！
谢谢！